Cannabidiol attenuates behavioral changes in a rodent model of schizophrenia through 5-HT1A, but not CB1 and CB2 receptors.

Pharmacological Research : the Official Journal of the Italian Pharmacological Society
Naielly Rodrigues da SilvaFrancisco S Guimarães

Abstract

Preclinical and clinical data indicate that cannabidiol (CBD), a non-psychotomimetic compound from the Cannabis sativa plant, can induce antipsychotic-like effects. In an animal model of schizophrenia based on the antagonism of NMDA receptors, the behavioral and molecular changes induced by repeated treatment with the NMDA receptor antagonist MK-801 were prevented when CBD was co-administered with MK-801. It is unknown, however, if CBD would reverse these changes once they have been established. Thus, in the present study we used male C57BL/6J mice, 6 weeks old, to evaluate whether daily CBD injection for seven days, starting after the end of the repeated treatment with MK-801 for 14 days, would reverse MK-801-induced deficits in the social interaction (SI) and novel object recognition (NOR) tests, which have been used to investigate the negative and cognitive symptoms of schizophrenia, respectively. We also assessed whether CBD effects would be blocked by pretreatment with AM251, a CB1 receptor antagonist, AM630, a CB2 receptor antagonist, or WAY100635, a 5-HT1A receptor antagonist. CBD and the second-generation antipsychotic clozapine, used as a positive control, attenuated the impairments in the SI and NOR tests induced by r...Continue Reading

References

Jan 1, 1991·Psychopharmacology·A W ZuardiJ M Cunha
Jan 1, 1990·Psychopharmacology·F S GuimarãesA W Zuardi
Jul 15, 1993·The New England Journal of Medicine·J M AlvirJ A Schaaf
Aug 1, 1995·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·A C LahtiC A Tamminga
May 10, 2001·Biological Psychiatry·T SumiyoshiH Y Meltzer
Jun 6, 2003·Neuroscience and Biobehavioral Reviews·Albert Hung Choy Wong, Hubert H M Van Tol
Sep 13, 2003·Lipids in Health and Disease·Nicola De MarchiVincenzo Di Marzo
May 26, 2004·Life Sciences·Viviane M C GuimarãesFrancisco S Guimarães
Apr 21, 2005·European Journal of Pharmacology·Fabrício A Moreira, Francisco S Guimarães
Sep 21, 2005·The New England Journal of Medicine·Jeffrey A LiebermanUNKNOWN Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators
Nov 25, 2005·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Llorenç Díaz-MataixFrancesc Artigas
Jun 6, 2006·Journal of Pharmacological and Toxicological Methods·V Bertaina-AngladeC Drieu la Rochelle
Feb 15, 2007·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Martina BallmaierPierFranco Spano
Mar 30, 2007·Progress in Neuro-psychopharmacology & Biological Psychiatry·Tomiki SumiyoshiMasayoshi Kurachi
Mar 30, 2007·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Leah H RubinPauline M Maki
Jan 1, 2008·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Hiroko HagiwaraKenji Hashimoto
Mar 4, 2008·The British Journal of Psychiatry : the Journal of Mental Science·Shôn Lewis, Jeffrey Lieberman
May 3, 2008·Behavioural Brain Research·Shikha Snigdha, Joanna C Neill
May 13, 2008·Neuroscience and Biobehavioral Reviews·Vera Bubeníková-ValesováCyril Höschl
Jul 18, 2009·The International Journal of Neuropsychopharmacology·Alexandre SeillierAndrea Giuffrida
Nov 26, 2009·Biological Psychiatry·Hiroki IshiguroTadao Arinami
Dec 17, 2009·British Journal of Pharmacology·T V ZanelatiSâmia R L Joca
Feb 18, 2010·The International Journal of Neuropsychopharmacology·Analía BortolozziFrancesc Artigas
Aug 10, 2010·Behavioural Pharmacology·Plinio C CasarottoFrancisco S Guimarães
Sep 8, 2010·Current Psychiatry Reports·Elizabeth HansonChristian Kohler
Sep 17, 2010·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Tyler A LeshCameron S Carter
Oct 7, 2010·The International Journal of Neuropsychopharmacology·Erica ZamberlettiDaniela Parolaro
Mar 23, 2011·Current Opinion in Pharmacology·H Y Meltzer, B W Massey
Mar 25, 2011·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Antonio Ortega-AlvaroJorge Manzanares
Apr 5, 2011·Behavioural Brain Research·Anand GururajanDaniel Thomas Malone
Jun 29, 2012·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Masakuni HoriguchiHerbert Y Meltzer
Oct 31, 2012·Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences·Alline Cristina CamposFrancisco Silveira Guimarães
Jun 25, 2013·Progress in Neuro-psychopharmacology & Biological Psychiatry·Felipe V GomesFrancisco S Guimarães
Jul 5, 2013·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Miquel BioqueUNKNOWN FLAMM-PEPs study—Centro de Investigacio´n Biome´dica en Red de Salud Mental
Jan 15, 2014·Current Pharmaceutical Design·Chun-Yuan LinHsien-Yuan Lane
Apr 8, 2014·Psychopharmacology·Ramy KhellaDaniel T Malone
Jan 27, 2015·The International Journal of Neuropsychopharmacology·Felipe V GomesFrancisco S Guimarães

❮ Previous
Next ❯

Citations

Sep 21, 2020·Neuroscience·Charalampos BrakatselosKaterina Antoniou
Dec 8, 2020·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·Martina Di BartolomeoVincenzo Micale
Dec 18, 2020·Frontiers in Psychiatry·Isadora L CortezFelipe V Gomes
Feb 23, 2021·Frontiers in Pharmacology·Franciele F ScaranteAlline C Campos
Feb 23, 2021·Frontiers in Pharmacology·Cássio Morais LossVanessa Costhek Abílio
Apr 11, 2021·Molecular Psychiatry·Alexandre ValléeJean-Noël Vallée
May 29, 2021·Progress in Neuro-psychopharmacology & Biological Psychiatry·Andreza Buzolin SonegoFrancisco Silveira Guimarães
Jul 14, 2021·Psychopharmacology·Edward ChesneyPhilip McGuire
Jul 14, 2021·Future Medicinal Chemistry·Agnieszka JankowskaGrażyna Chłoń-Rzepa
Sep 4, 2021·European Journal of Pharmacology·Elena Reyes-CuapioEric Murillo-Rodríguez

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here